🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “loncastuximab tesirine” Clear

  1. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  2. CYTARABINE , LONCASTUXIMAB TESIRINE, RITUXIMAB, BENDAMUSTINE

    Fondazione Telethon ETS

    Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  3. Loncastuximab Tesirine

    ADC Therapeutics SA

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  4. Loncastuximab Tesirine

    ADC Therapeutics SA

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    4 trials

  5. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  6. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  8. Loncastuximab tesirine

    ADC Therapeutics SA

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  9. Loncastuximab tesirine

    ADC Therapeutics SA

    Post-transplant Lymphoproliferative Disorder

    phase 2 small molecule active

    1 trial

  10. Loncastuximab tesirine 150 µg/Kg

    ADC Therapeutics SA

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  11. A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

    ADC Therapeutics SA

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  12. Loncastuximab Tesirine

    ADC Therapeutics SA

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  13. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  14. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  15. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources